CoChat
Sign Up
Cited by 186Smoking Behavior and CessationSubstance Abuse Treatment and OutcomesBehavioral Health and Interventions

The DOI matches its Crossref record; 250 of the 252 references it cites were found in a registry or an index.

Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation

Open access
Hartmann-Boyce, Jamie, Hong, Bosun, Livingstone-Banks, Jonathan, Wheat, Hannah, Fanshawe, Thomas R·2019·Cochrane Database of Systematic Reviews
DOI 10.1002/14651858.cd009670.pub4PMC PMC6549450
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Pharmacotherapies for smoking cessation increase the likelihood of achieving abstinence in a quit attempt. It is plausible that providing support, or, if support is offered, offering more intensive support or support including particular components may increase abstinence further. OBJECTIVES: To evaluate the effect of adding or increasing the intensity of behavioural support for people using smoking cessation medications, and to assess whether there are different effects depending on the type of pharmacotherapy, or the amount of support in each condition. We also looked at studies which directly compare behavioural interventions matched for contact time, where pharmacotherapy is provided to both groups (e.g. tests of different components or approaches to behavioural support as an adjunct to pharmacotherapy). SEARCH METHODS: We searched the Cochrane Tobacco Addiction Group Specialised Register, clinicaltrials.gov, and the ICTRP in June 2018 for records with any mention of pharmacotherapy, including any type of nicotine replacement therapy (NRT), bupropion, nortriptyline or varenicline, that evaluated the addition of personal support or compared two or more intensities of behavioural support. SELECTION CRITERIA: Randomised or quasi-randomised controlled trials in which all participants received pharmacotherapy for smoking cessation and conditions differed by the amount or type of behavioural support. The intervention condition had to involve person-to-person contact (defined as face-to-face or telephone). The control condition could receive less intensive personal contact, a different type of personal contact, written information, or no behavioural support at all. We excluded trials recruiting only pregnant women and trials which did not set out to assess smoking cessation at six months or longer. DATA COLLECTION AND ANALYSIS: For this update, screening and data extraction followed standard Cochrane methods. The main outcome measure was abstinence from smoking after at least six months of follow-up. We used the most rigorous definition of abstinence for each trial, and biochemically-validated rates, if available. We calculated the risk ratio (RR) and 95% confidence interval (CI) for each study. Where appropriate, we performed meta-analysis using a random-effects model. MAIN RESULTS: Eighty-three studies, 36 of which were new to this update, met the inclusion criteria, representing 29,536 participants. Overall, we judged 16 studies to be at low risk of bias and 21 studies to be at high risk of bias. All other studies were judged to be at unclear risk of bias. Results were not sensitive to the exclusion of studies at high risk of bias. We pooled all studies comparing more versus less support in the main analysis. Findings demonstrated a benefit of behavioural support in addition to pharmacotherapy. When all studies of additional behavioural therapy were pooled, there was evidence of a statistically significant benefit from additional support (RR 1.15, 95% CI 1.08 to 1.22, I² = 8%, 65 studies, n = 23,331) for abstinence at longest follow-up, and this effect was not different when we compared subgroups by type of pharmacotherapy or intensity of contact. This effect was similar in the subgroup of eight studies in which the control group received no behavioural support (RR 1.20, 95% CI 1.02 to 1.43, I² = 20%, n = 4,018). Seventeen studies compared interventions matched for contact time but that differed in terms of the behavioural components or approaches employed. Of the 15 comparisons, all had small numbers of participants and events. Only one detected a statistically significant effect, favouring a health education approach (which the authors described as standard counselling containing information and advice) over motivational interviewing approach (RR 0.56, 95% CI 0.33 to 0.94, n = 378). AUTHORS' CONCLUSIONS: There is high-certainty evidence that providing behavioural support in person or via telephone for people using pharmacotherapy to stop smoking increases quit rates. Increasing the amount of behavioural support is likely to increase the chance of success by about 10% to 20%, based on a pooled estimate from 65 trials. Subgroup analysis suggests that the incremental benefit from more support is similar over a range of levels of baseline support. More research is needed to assess the effectiveness of specific components that comprise behavioural support.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd009670.pub4

Cites

250 of 250 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 5

  1. Heffner, 2014, Effects of two telephone-delivered smoking cessation interventions on hazardous drinking rates: ACT vs. CBT, Alcoholism, Clinical and Experimental Research, 38, 137A
  2. Huber, 2003, Smoking cessation: a comparison of behavior therapy, nicotine replacement therapy and their combination, Verhaltenstherapie und Verhaltenshmedizin, 24, 167
  3. McCarthy, 2007, Mechanisms of tobacco cessation treatment: self-report mediators of counseling and bupropion sustained release treatment, Dissertation Abstracts International: Section B: The Sciences and Engineering, 67, 5414
  4. Strong, 2009, Impact of bupropion and cognitive-behavioral treatment for depression on positive affect, negative affect, and urges to smoke during cessation treatment, Nicotine & Tobacco Research, 11, 1142, 10.1093/ntr/ntp111 · DOI
  5. Fiore, 2008, Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. AHRQ publication No. 00-0032

Cited by

Sorted by citations

See all 186

Related

See all

Metadata

Authors
Hartmann-Boyce, J., Hong, B., Livingstone-Banks, J., Wheat, H., & Fanshawe, T. R.
Affiliations
  • University of Oxford; Nuffield Department of Primary Care Health Sciences; Radcliffe Observatory Quarter Woodstock Road Oxford UK OX2 6GG
  • Birmingham Dental Hospital (GB)
  • University of Oxford (GB)
ORCID
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2019-06-05
Volume
2019
Issue
6
Pages
CD009670-CD009670
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
DOI
10.1002/14651858.cd009670.pub4
PMC
PMC6549450
OpenAlex
W2948298121
Cited by
186
References
252
Citations by year
2026: 10 · 2025: 20 · 2024: 21 · 2023: 34 · 2022: 36 · 2021: 36 · 2020: 22 · 2019: 5
FWCI
2.91
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • Cochrane Database of Systematic Reviews (publishedVersion, other-oa)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Open Research Exeter (University of Exeter) (publishedVersion)
  • Figshare (submittedVersion)
  • PEARL (University of Plymouth) (submittedVersion)
Funders
  • National Institute for Health and Care Research (16/114/20, SRP/16/114/20, ACF-2017-09-014)
  • Department of Health and Social Care
  • Evidence Synthesis Programme
  • NIHR Oxford Biomedical Research Centre
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Social Sciences › Psychology › Applied Psychology › Behavioral Health and Interventions
Keywords
smoking cessation, behavioral support, pharmacotherapy, nicotine replacement therapy, bupropion, nortriptyline, varenicline, smoking abstinence, telephone support, face-to-face support, support intensity, nicotine dependence, relapse, risk of bias, tobacco control, harm reduction funding
MeSH terms
Varenicline, Behavior Therapy, Combined Modality Therapy, Female, Humans, Nortriptyline, Pregnancy, Smoking, Tobacco Use Disorder, Smoking Cessation, Bupropion, Nicotinic Agonists, Tobacco Use Cessation Devices

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review